William Krasner, NP
Family · Little Egg Harbor Twp, NJNPI 1588209654
Payments from drug & device makers
Across 76 payments — averaging $60.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- AstraZeneca$213
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$210
- Lilly USA, LLC$128
- Exact Sciences$69
- Novo Nordisk$59
- plus $371 from 16 others
What the payments were for
- Travel & lodging$2,44053%
- Food & beverage$2,17447%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 36 | $3,565 |
| AstraZeneca | 8 | $213 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $210 |
| Lilly USA, LLC | 3 | $128 |
| Exact Sciences | 3 | $69 |
| Novo Nordisk | 3 | $59 |
| Pfizer | 3 | $50 |
| GSK | 1 | $38 |
| Amgen | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| Corcept Therapeutics | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Bayer | 1 | $24 |
| Insulet Corporation | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $16 |
| AbbVie | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Philips North America LLC | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$1,355
- InPen$921
- CAPLYTA$210
- MINIMED 780G$171
- FARXIGA$114
How this compares
$4,615 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 51 | $63,068 |
| JanuviaSitagliptin Phosphate | 37 | $46,509 |
| FarxigaDapagliflozin Propanediol | 39 | $46,032 |
| OzempicSemaglutide | 23 | $43,921 |
| EliquisApixaban | 47 | $38,769 |
| RybelsusSemaglutide | 11 | $15,575 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $13,387 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $9,287 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $8,984 |
| Repatha SureclickEvolocumab | 12 | $8,833 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $6,060 |
| Atorvastatin Calcium | 381 | $4,854 |
| Icosapent Ethyl | 11 | $4,571 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 139 | $4,407 |
| Humalog Kwikpen U-100Insulin Lispro | 19 | $4,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $16 | $63,06851 claims |
| Novo NordiskOzempic, Rybelsus | $59 | $59,49634 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $213 | $55,31852 claims |
| PfizerEliquis | $50 | $38,76947 claims |
| GSKBreo Ellipta | $38 | $13,38724 claims |
| Lilly USA, LLCHumalog | $128 | $97512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.
Other family in Little Egg Harbor Twp
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- Angie GarciaWest New York$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Megan FiloramoMorristown$53K
- Shawn DenningToms River$29K
- Kimberly ClementeEatontown$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.